Enveric Biosciences Sells Cancer Patents As It Paves Way For Mental Health Treatments [Benzinga]
Friday, February 23, 2024 1 min read
Key Takeaway: Enveric Biosciences Inc. has announced the sale of its cancer-related patent portfolio, although the financial details of the transaction remain undisclosed. The portfolio includes patents issued in several countries, including the U.S., Australia, and Europe, along with pending applications in Canada, Israel, and Korea. This strategic move is aimed at reallocating resources towards mental health treatments.
Price reaction · baseline $180.018 (2024-02-23T14:53:00.000Z) · hit during market hours · clean, no other ENVB news in the window
day 0 close · peak
-2%
Market Sentiment Analysis
POSITIVE FACTORS
Enveric Biosciences is focusing on mental health treatments.
The sale of cancer-related patents may provide financial resources.
The patent portfolio covers multiple countries, indicating a broad reach.
Full Press Release Details
Enveric Biosciences Inc. said on Friday it has agreed to sell one of its cancer-related patent portfolios. The Cambridge, Massachusetts-based company didn’t disclose the amount. The divested portfolio includes patents issued in the U.S., Australia, Canada, China, Europe and Japan, with patent applications pending in Canada, Israel, and Korea, the company said in a press release.
Full Article >>
Frequently Asked Questions
What patents did Enveric Biosciences sell?
Enveric Biosciences sold its cancer-related patent portfolio.
Did Enveric disclose the sale amount?
No, the company did not disclose the amount from the sale.
In which countries are the patents issued?
The patents are issued in the U.S., Australia, Canada, China, Europe, and Japan.
What is the purpose of the patent sale?
The sale aims to reallocate resources towards mental health treatments.